Clinical Trials Logo

Clinical Trial Summary

Urinary Activin A as amarker for assessement of acute kidney injury severity in patient admitted at Assuit University Hospital


Clinical Trial Description

Acute kidney injury has been ahealth problem all over the world , It's prevelance in developing and developed countries is increasing due to pre renal , renal , post renal causes . Estimates of AKI prevalence range from <1% to 66%. These variations can be explained by not only population differences but also inconsistent use of standardized AKI classification criteria. The aetiology and incidence of AKI also differ between high-income and low-to-middle-income countries.(1) - It can be presented in different stages according to AKIN classification (stage l (Increase in serum creatinine ≥0.3md/dl (≥26.4μmol/l) or increase to >150% to 200% (1.5 fold to 2 fold) from baseline , and urine output (<0.5 ml/kg/h for >6 h )) - stage ll (Increase to >200% to 300% (>2 fold to 3 fold) from baseline) , and urine output (<0.5 ml/kg/h for >12 h )) - stage lll(Increase in serum creatinine to >300% (>3 fold) from baseline, or serum creatinine >4.0mg/dl (>354μmol/l) with acute increase of atleast 0.5mg/dl ) Urine output(<0.3ml/kg/hr for 24 hours, or anuria for 12 hours). (2) - In ischemic kidney, there is acytokine belong to the transforming growth factor (TGF)-B ( Activin A) that regulates the growth and differantiation of cell in variuos organs was significantly increasd in ischemic kidney . (3) - level of Activin A in urine correlate to the severity of the acute kidney injury (AKI), as the level of urinary Activin A in first stages of acute kidney injury is less than the second and third stages . (4) - so follow up of urinary Activin A in patients with acute kidney injury can be avery useful biomarker for assessement of severity of acute kidney injury. (4) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06188533
Study type Observational
Source Assiut University
Contact
Status Not yet recruiting
Phase
Start date March 1, 2024
Completion date December 5, 2026